Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Key Points:

• Eli Lilly reported a 39% increase in Q3 2026 revenue to $24.4 billion, driven mainly by strong sales of Mounjaro and Zepbound, with U.S. revenue up 34% and international revenue up 47%.
• Q3 2026 earnings per share (EPS) rose 16% on a reported basis to $7.22 and 7% on a non-GAAP basis to $7.48, despite higher acquired in-process research and development (IPR&D) charges of $4.57 per share compared to $0.71 in Q3 2025.
• The company raised its full-year 2026 revenue guidance by $5.5 billion to a range of $91.0 to $92.0 billion and increased non-GAAP EPS guidance to $35.00 to $36.00, factoring in recent business development charges.
• Regulatory milestones included FDA approvals for Mounjaro to reduce cardiovascular risk, Onswik basal insulin, Inluriyo with Verzenio for breast cancer, and an expanded indication for Jaypirca in leukemia and lymphoma.
• Business development highlights featured the acquisitions of AtaiBeckley for mental health therapies and Merida Biosciences for autoimmune and allergic disease treatments, supporting Lilly’s strategic growth in neuroscience and immunology.